List of Excipients in Branded Drug ANAFRANIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	D&C RED NO. 33
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	D&C YELLOW NO. 10
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	FD&C YELLOW NO. 6
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	GELATIN
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	MAGNESIUM STEARATE
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	METHYLPARABEN
SpecGx LLC	ANAFRANIL	clomipramine hydrochloride	0406-9906	PROPYLPARABEN

Anafranil Excipient Strategy and Commercial Opportunities for Clomipramine

Last updated: September 24, 2026

Anafranil is the originator brand for clomipramine hydrochloride, an orally administered tricyclic antidepressant approved in the United States for obsessive-compulsive disorder. Its core product protection has expired, and commercial value now depends on formulation differentiation, tolerability, adherence, manufacturing efficiency, and market access rather than conventional molecule exclusivity.

The strongest opportunities are lactose-free or low-allergen capsules, lower-swallowing-burden dosage forms, modified-release products, pediatric formulations, and products designed to reduce treatment interruption during dose titration. A new formulation would likely require an ANDA if it is pharmaceutically equivalent to the reference product, or a 505(b)(2) application if it relies on a clinically differentiated dosage form or route. [1][2]

What is Anafranil and which excipients are used?

Anafranil contains clomipramine hydrochloride. U.S. labeling identifies capsule strengths of 25 mg, 50 mg, and 75 mg. The product is an immediate-release oral dosage form used primarily for OCD. [1]

The reference product uses conventional hard-gelatin capsule technology and common solid oral excipients. Exact excipient composition can differ by strength, market, manufacturing site, and regulatory filing. Commercial clomipramine products may use combinations of lactose, starch, colloidal silicon dioxide, magnesium stearate, gelatin, titanium dioxide, and approved capsule colorants. The specific composition for a proposed product must be controlled against the target reference listed drug and the applicable product label.

Functional role of the principal excipients

Excipient class	Typical function	Strategic relevance
Lactose or other diluent	Adds bulk and supports content uniformity	Creates an opportunity for lactose-free products
Pregelatinized starch or corn starch	Filler, binder, and disintegrant	Supports low-cost capsule or tablet manufacture
Colloidal silicon dioxide	Glidant and flow aid	Helps manage low-dose blend uniformity
Magnesium stearate	Lubricant	Requires control because excess lubrication can slow dissolution
Gelatin	Capsule shell	Creates animal-origin and dietary-positioning issues
Titanium dioxide and colorants	Capsule identification and branding	Relevant to global regulatory and consumer preferences
Sodium lauryl sulfate or surfactant systems	Wetting and dissolution support	May improve performance in a differentiated dosage form

Clomipramine is administered at relatively low capsule fill weights compared with many immediate-release products. Blend uniformity, segregation control, and accurate filling are therefore important manufacturing considerations. The highest commercial risk is not normally raw-material cost. It is failure to demonstrate consistent assay, dissolution, content uniformity, and bioequivalence.

What FDA regulatory status does Anafranil have?

Anafranil is an FDA-approved small-molecule drug, not a biologic. It is regulated through the New Drug Application and Abbreviated New Drug Application pathways rather than the biosimilar pathway. The reference product was approved in 1989 for OCD. [1]

Regulatory issue	Anafranil status
Active ingredient	Clomipramine hydrochloride
Drug class	Tricyclic antidepressant
U.S. dosage form	Immediate-release capsules
U.S. strengths	25 mg, 50 mg, 75 mg
Primary approved indication	Obsessive-compulsive disorder
FDA pathway for equivalent product	ANDA
FDA pathway for differentiated formulation	Potentially 505(b)(2)
Biosimilar pathway	Not applicable
Pediatric relevance	High, because OCD treatment includes adolescents and younger patients under clinical supervision
Controlled-substance classification	Not federally scheduled as a controlled substance

The product has established safety and clinical-use history, but clomipramine carries class-related risks, including anticholinergic effects, cardiovascular effects, central nervous system effects, and overdose toxicity. A new formulation that changes exposure, absorption rate, or dosing frequency would require careful pharmacokinetic and safety justification. [1][3]

When does Anafranil lose exclusivity?

Anafranil lost practical U.S. market exclusivity years ago. Its current competitive environment is generic, and the principal commercial question is formulation differentiation rather than basic market entry.

The original composition and use patents associated with clomipramine are expired or no longer commercially blocking in the United States. The FDA Orange Book should be used to confirm current listed patents and exclusivity for a specific reference product and dosage form. [2]

Exclusivity timeline

Milestone	Approximate status
Original U.S. approval	1989
Original small-molecule exclusivity	Expired
Original product and use patent estate	Expired or commercially non-blocking
Generic clomipramine availability	Established
Current competitive barrier	Formulation, manufacturing, regulatory execution, and distribution
Biosimilar exposure	None

The absence of active molecule exclusivity does not eliminate the possibility of new patent protection. A sponsor can seek patents covering a new release profile, multiparticulate system, capsule composition, taste-masking approach, manufacturing process, or specific excipient combination. Those patents would protect the new product only to the extent that the claims are novel, non-obvious, adequately supported, and infringed by competing products.

What patents protect Anafranil today?

No commercially meaningful originator patent barrier is expected to prevent generic clomipramine competition. The more relevant IP question is whether a new clomipramine product can obtain formulation or method-of-use protection.

Patent opportunities for a new clomipramine product

Patent category	Potential claim subject	Commercial value
Modified release	Once-daily or delayed-release clomipramine	Could reduce dosing burden and support premium pricing
Multiparticulates	Pellets, beads, or coated granules	May separate release phases and improve dose control
Pediatric formulation	Liquid, mini-tablet, sprinkle capsule, or orally disintegrating form	Targets adherence and swallowing limitations
Excipient system	Specific diluent, binder, lubricant, surfactant, or coating combination	Usually narrower protection
Stability	Moisture-control or oxidation-control composition	Protects manufacturing and shelf-life attributes
Method of use	Dose titration, treatment subgroup, or adverse-effect reduction	Requires credible clinical support
Manufacturing process	Low-shear blending, granulation, coating, or encapsulation method	Can create a manufacturing barrier, but may be difficult to detect in finished products

Excipient-only claims are often vulnerable when they recite conventional materials used for their established functions. Stronger protection would generally require a demonstrated technical effect, such as an unexpected dissolution profile, improved stability, reduced variability, lower impurity formation, or clinically relevant tolerability improvement.

What formulations are protected by an Anafranil excipient strategy?

The most commercially defensible strategy is to pair a patient-facing advantage with measurable pharmaceutical performance.

1. Lactose-free capsules

A lactose-free capsule could address patients who avoid lactose or prescribers who prefer a simpler excipient profile. The product would compete with generic clomipramine on tolerability positioning and institutional formulary specifications.

The opportunity is commercially accessible but not inherently strong from a patent perspective. Lactose substitution with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch would generally require a composition and performance rationale. Label differentiation and pharmacy-channel distribution may be more important than patent exclusivity.

2. Plant-based capsule shells

A hypromellose capsule could target vegetarian, religious, or animal-origin-sensitive consumers. This approach may be attractive in international markets and specialty pharmacies.

The capsule shell alone is unlikely to support a broad blocking patent. The stronger strategy is to combine the shell with a moisture-control system, enhanced content uniformity, or a differentiated release design.

3. Modified-release clomipramine

Clomipramine is commonly titrated, and adverse effects can limit adherence. A modified-release product could seek a smoother exposure profile or once-daily administration.

This is the highest-value formulation opportunity but also the most technically demanding. A sponsor would need to address:

• Dose dumping risk.
• Food effects.
• Pharmacokinetic equivalence or clinical bridging.
• Titration flexibility.
• Conversion from immediate-release treatment.
• Dose strength availability.
• Exposure to active metabolites.
• Safety during overdose or accidental ingestion.

A successful modified-release product could support a 505(b)(2) strategy and potentially obtain formulation patents with greater commercial value than a simple excipient substitution.

4. Pediatric liquid or multiparticulate product

OCD treatment includes pediatric and adolescent patients. Capsules may be unsuitable for some patients, especially during initiation or dose adjustment. A liquid, mini-tablet, sprinkle capsule, or multiparticulate product could improve administration.

Key technical issues include clomipramine hydrochloride solubility, chemical stability, taste, dosing accuracy, preservative compatibility, and packaging. A liquid product would need a robust stability program and child-resistant packaging. A sprinkle product would need data showing that opening the capsule does not alter dose delivery or release behavior.

5. Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty and improve convenience. The product must manage the bitter taste associated with many tricyclic compounds.

Taste masking may use polymer coatings, ion-exchange resins, cyclodextrin systems, lipid-based barriers, or multiparticulate encapsulation. The commercial value depends on whether the product produces a meaningful adherence benefit without increasing cost or delaying disintegration.

How strong is the patent estate for a new Anafranil formulation?

A new clomipramine formulation can have a moderate patent position, but the strength depends on claim scope and the evidence supporting the formulation.

Strategy	Expected patent strength	Development complexity	Commercial potential
Lactose-free capsule	Low to moderate	Low	Moderate
Hypromellose capsule	Low to moderate	Low	Moderate
New color or shell design	Low	Low	Low
Pediatric liquid	Moderate	Moderate	Moderate to high
Sprinkle multiparticulate	Moderate to high	High	High
Once-daily modified release	High if clinically differentiated	High	High
Orally disintegrating tablet	Moderate	Moderate to high	Moderate
New method of use	Variable	High	High if supported
Manufacturing process patent	Moderate	Moderate	Defensive

Formulation patents should avoid claiming only routine excipient substitutions. The strongest filings would connect composition to a measurable result, such as a defined dissolution range, lower impurity level, improved storage stability, reduced pharmacokinetic fluctuation, or improved patient administration.

What generic entry risks exist for Anafranil?

Generic entry risk is already established for immediate-release clomipramine capsules. A new entrant would face several competitive layers.

Immediate-release generic risk

This is the highest-risk segment. Products can compete on price, supply reliability, authorized-generic arrangements, wholesaler access, and formulary status. New entrants are unlikely to obtain meaningful pricing power unless they solve a documented supply or excipient problem.

505(b)(2) crossover risk

A differentiated product may obtain regulatory protection or patents, but generic applicants could challenge the patents through Paragraph IV certifications if the patents are listed in the Orange Book. The sponsor must distinguish between patents that protect the approved product and patents that are difficult to list or enforce.

Substitution risk

Pharmacy substitution rules vary by jurisdiction and product. A modified-release or liquid product may avoid direct substitution with immediate-release capsules, but prescriber adoption and payer coverage become more important.

Safety-driven switching risk

A product positioned around lower peak exposure or improved tolerability may attract clinicians, but the claim requires clinical evidence. Excipient changes alone will not establish lower anticholinergic or cardiovascular risk if systemic exposure remains materially similar.

Which companies are challenging Anafranil?

The U.S. market has been challenged primarily by generic manufacturers rather than by biosimilar companies. Generic clomipramine products have historically been marketed by multiple manufacturers, including major generic suppliers and authorized distributors. The active competitive set changes over time as companies enter, discontinue, or change labeler status.

The principal competitive categories are:

1. Immediate-release clomipramine capsule manufacturers.
2. Contract manufacturers supplying private-label products.
3. Specialty pharmaceutical companies developing modified-release or pediatric formulations.
4. Manufacturers of alternative OCD therapies, including selective serotonin reuptake inhibitors.
5. Compounding pharmacies serving liquid or nonstandard-dose needs.

A commercial entrant should analyze current FDA product listings, labeler status, shortage records, wholesaler availability, and payer formulary placement before sizing the market. [2][4]

What is the commercial opportunity for Anafranil excipient innovation?

The commercial opportunity is niche but actionable. A conventional generic faces low price ceilings. A differentiated product can create value by solving an administration, supply, or tolerability problem.

Opportunity ranking

Product concept	Target customer	Revenue potential	Main barrier
Low-cost equivalent capsule	Retail and institutional pharmacies	Low	Price competition
Lactose-free capsule	Retail, specialty, and international markets	Moderate	Limited willingness to pay
Vegetarian capsule	Retail and international markets	Moderate	Weak exclusivity
Pediatric liquid	Pediatric psychiatry and caregivers	Moderate to high	Stability and taste
Sprinkle capsule	Pediatric and adherence-focused markets	High	Product development and evidence
Modified-release capsule	Adult OCD and specialty psychiatry	High	PK, safety, and payer adoption
Orally disintegrating tablet	Patients with swallowing barriers	Moderate	Taste masking and competition
Contract-manufactured private label	Regional distributors	Moderate	Supply and margin pressure

Revenue exposure from legacy Anafranil itself is difficult to separate from the broader clomipramine market because the product is mature and genericized. The more relevant forecast should model net sales by dosage form, channel, payer mix, and price relative to generic capsules.

How does Anafranil compare with competing OCD drugs?

Clomipramine competes with SSRIs and other branded or generic treatments for OCD. Its formulation opportunity is shaped by the fact that physicians already have lower-cost oral alternatives.

Product class	Formulation advantage	Main commercial weakness
Clomipramine immediate-release	Established efficacy and low-cost generic access	Anticholinergic and other tolerability concerns
SSRI tablets and capsules	Broad availability and simpler prescribing	Generic price competition
Extended-release antidepressants	Reduced dosing frequency in some products	May not have the same OCD positioning
Liquid antidepressants	Pediatric and swallowing advantages	Stability, taste, and packaging cost
Specialty formulations	Potential adherence or tolerability differentiation	Higher development and reimbursement burden

A clomipramine formulation will need a clear reason to replace or supplement an SSRI. "Lactose-free" alone is unlikely to justify a major premium. Once-daily dosing, pediatric usability, or a demonstrated exposure and tolerability benefit has stronger commercial logic.

What manufacturing and IP barriers affect clomipramine products?

Manufacturing barriers are manageable for immediate-release capsules but increase sharply for modified-release and liquid products.

Critical manufacturing controls include:

• Uniform distribution of low-dose clomipramine in the blend.
• Control of lubricant concentration and mixing time.
• Moisture control during encapsulation and storage.
• Capsule-shell compatibility.
• Dissolution reproducibility across strengths.
• Control of degradation products.
• Packaging protection from humidity and light.
• Cleaning validation for a potent, pharmacologically active compound.
• Stability after opening for liquid or sprinkle products.

For a differentiated product, the intellectual-property package should combine composition claims, process claims, release-profile claims, and, where supportable, method-of-use claims. Geographic coverage should prioritize the United States, European Union, United Kingdom, Canada, Japan, Australia, and major emerging markets with established OCD treatment demand. National phase timing and patent-term calculations must be assessed separately for each family.

What should a commercial development plan prioritize?

A practical development sequence is:

1. Select a target product profile focused on one measurable patient or manufacturing problem.
2. Screen excipient compatibility and clomipramine stability.
3. Compare dissolution and content uniformity against the reference product.
4. Assess whether the product fits an ANDA or requires a 505(b)(2) strategy.
5. File composition and process patents before public disclosure.
6. Develop a regulatory package around bioequivalence, bridging, or clinical benefit.
7. Confirm Orange Book listing eligibility for patents covering the approved product.
8. Secure manufacturing capacity and global supply controls.
9. Test payer willingness to cover the differentiated product.
10. Launch through specialty psychiatry, pediatric channels, or targeted retail distribution.

The preferred asset is a formulation with a visible clinical or operational advantage and a patent claim tied to that advantage. A minor excipient change can improve procurement access, but it rarely creates durable pricing power.

Key Takeaways

• Anafranil is clomipramine hydrochloride, an old small-molecule product with expired practical exclusivity.
• Immediate-release generic competition is established and limits commodity pricing.
• The strongest commercial opportunities are modified release, pediatric delivery, sprinkle multiparticulates, and stable liquid formulations.
• Lactose-free and vegetarian capsules are feasible but usually have limited patent strength.
• Excipient patents are stronger when they demonstrate improved stability, dissolution, dose uniformity, or administration.
• Biosimilar risk does not apply because clomipramine is a small molecule.
• An ANDA is appropriate for a pharmaceutically equivalent product; a 505(b)(2) application may be appropriate for a clinically differentiated dosage form.
• Orange Book and current FDA product data should control any live assessment of listed patents, approved manufacturers, and market availability.
• The best commercial strategy is to link excipient selection to a measurable adherence, safety, pediatric, or manufacturing benefit.

Frequently Asked Questions

Can a lactose-free Anafranil generic obtain meaningful patent protection?

Usually only limited protection is available from lactose removal alone. Patent value improves if the replacement excipient system produces an unexpected stability, dissolution, or content-uniformity result.

Is a liquid clomipramine product commercially viable?

Yes, particularly for pediatric patients and people who cannot swallow capsules. The main development issues are taste, chemical stability, preservative compatibility, dosing accuracy, and packaging.

Would a once-daily clomipramine product require clinical trials?

The regulatory requirement depends on the formulation and proposed labeling. A modified-release product generally requires pharmacokinetic evidence and may require clinical data if it makes a new therapeutic or tolerability claim.

Can a clomipramine formulation patent be listed in the Orange Book?

A patent may be listable if it claims the approved drug, its formulation, or an approved method of use and satisfies FDA listing requirements. Process-only and nonqualifying patents may not provide the same Orange Book leverage. [2]

Are generic manufacturers likely to challenge a new Anafranil formulation?

Yes, if the product gains meaningful sales and its patents are listed or otherwise enforceable. The risk is greatest for broad modified-release or pediatric formulation claims that materially limit substitution.

References

1. U.S. Food and Drug Administration. (2017). Anafranil (clomipramine hydrochloride) capsules prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2009). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.